Search Results - "Oberg, J.A"

Changes in Patient-Reported Outcomes Among Pediatric Leukemia and Lymphoma Patients During the First 2-Years Post Allogeneic Stem Cell Transplantation (alloSCT) by Oberg, J.A, Morris, E, Cairo, M, Kelly, K.M

Get full text

Phase Ib Study Of Patients Receiving Topotecan By Convection-Enhanced Delivery (Ced) For Recurrent Malignant Gliomas: Neurocognitive Functioning And Quality Of Life Outcomes by Oberg, J.A, Dave, A, Bruce, J.N, Sands, S.A

Get full text

Clinical Implementation of Genomic Sequencing in Pediatric Oncology: Identification and Valuation of Resources and Costs Associated with Next-Generation Sequencing by Oberg, J.A, Sireci, A.N, Mansukhani, M.M, Nagy, P.L, Glade Bender, J.L, Kung, A.L

Get full text

Reduced Toxicity Conditioning (RTC) and Allogeneic Stem Cell Transplantation (AlloSCT) for Pediatric Sickle Cell Disease (SCD): Significant Improvement in Physical Functioning by Oberg, J.A, Sands, S.S, Bhatia, M, Morris, E, Cairo, M.S

Get full text

PCN165 - Changes in Patient-Reported Outcomes Among Pediatric Leukemia and Lymphoma Patients During the First 2-Years Post Allogeneic Stem Cell Transplantation (alloSCT) by Oberg, J.A., Morris, E., Cairo, M., Kelly, K.M.

Get full text

PCN115 - Phase Ib Study Of Patients Receiving Topotecan By Convection-Enhanced Delivery (Ced) For Recurrent Malignant Gliomas: Neurocognitive Functioning And Quality Of Life Outcomes by Oberg, J.A., Dave, A., Bruce, J.N., Sands, S.A.

Get full text

PCN175 - Clinical Implementation of Genomic Sequencing in Pediatric Oncology: Identification and Valuation of Resources and Costs Associated with Next-Generation Sequencing by Oberg, J.A., Sireci, A.N., Mansukhani, M.M., Nagy, P.L., Glade Bender, J.L, Kung, A.L.

Get full text

Pediatric allo-SCT for malignant and non-malignant diseases: impact on health-related quality of life outcomes by Oberg, J A, Bender, J G, Morris, E, Harrison, L, Basch, C E, Garvin, J H, Sands, S A, Cairo, M S

“…The objective of this study was prospectively to investigate the health-related quality of life (HRQOL) of 80 pediatric recipients of allo-SCT for malignant…”
Get full text